For first-line treatment, the most commonly experienced toxicities for both the TNBC (n = 190) and HR+/HER2-negative (n = 110) subgroups were nausea (41.1% and 27.3%, respectively) and anemia (26.3% and 20.9%, respectively). The gene discussed is ERBB2; the disease is anemia.